Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Cash flows from operating activities:          
Net loss     $ (427,990) $ (169,167)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization     38,294 15,576  
Stock-based compensation     37,826 16,167  
Goodwill impairment $ 0   229,500    
Change in fair value of warrant liability       56,576  
Change in fair value of subscription agreement       2,920  
Amortization (accretion) of discount on investments     (305) 2,189  
Amortization of debt financing cost       9  
Amortization of deferred costs on convertible notes     276    
Provision for bad debt     1,038 316  
Acquired in-process research and development   $ 15,181   25,581  
Loss on disposal of property and equipment     209 19  
Foreign exchange (gains) losses on intercompany transactions, net     1,261    
Net increase (decrease) in accrued interest related to marketable securities     771 (414)  
Net unrealized (gain) loss on equity investment 300   6,172 1,880  
Net unrealized (gain) loss on other investments     745 (639)  
Deferred tax benefit     (1,602) (32,761)  
Change in fair value of contingent consideration (300)   (254) (166)  
Foreign currency transaction (gain) loss     (59)    
Changes in operating assets and liabilities:          
Accounts receivable     3,166 (8,476)  
Inventory     (31,195) (11,067)  
Prepaid expenses and other current assets     (969) (3,096)  
Other assets     1,196 (118)  
Accounts payable     (2,959) 4,243  
Accrued expenses and other current liabilities     (3,855) (9,294)  
Customer deposits     2,360 (1,298)  
Deferred revenue     (1,589) 1,295  
Change in right of use assets and lease liabilities, net     (2,850) (340)  
Other liabilities     24 6  
Net cash used in operating activities     (150,789) (110,059)  
Cash flows from investing activities:          
Purchases of property and equipment     (8,157) (4,145)  
Purchase of other investments       (3,620)  
Proceeds from other investments     3,155    
Purchase of equity investment       (20,000)  
Proceeds from sale of property and equipment     6    
Purchase of marketable securities     (158,404) (330,873)  
Proceeds from sales and maturities of marketable securities     205,650 163,882  
Proceeds from capital grant     200    
Cash paid to acquire in-process research and development       (21,220)  
Cash paid for acquisitions, net of cash acquired     (23) (191,146)  
Net cash provided by (used in) investing activities     42,427 (407,122)  
Cash flows from financing activities:          
Proceeds from the exercise of stock options     3,036 5,241  
Proceeds from the exercise of stock warrants       170,665  
Payment of taxes related to net share settlement upon vesting of restricted stock units     (230) (454)  
Repayment of loans     (421)    
Proceeds from issuance of convertible notes     115,000    
Costs incurred in connection with the issuance of convertible notes     (3,619)    
Repayment of term loan       (10,000)  
Net cash provided by financing activities     113,766 165,452  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (1,491) (56)  
Net increase (decrease) in cash, cash equivalents, and restricted cash     3,913 (351,785)  
Cash, cash equivalents, and restricted cash at beginning of period     68,258 484,137 $ 484,137
Cash, cash equivalents, and restricted cash at end of period 72,171 132,352 72,171 132,352 68,258
Supplemental disclosures of cash flow information          
Cash and cash equivalents 66,987 131,676 66,987 131,676 65,017
Restricted cash included in other current assets 4,072   4,072    
Restricted cash included in other noncurrent assets 1,112 676 1,112 676  
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 72,171 $ 132,352 72,171 132,352 $ 68,258
Supplemental cash flow information:          
Interest paid       137  
Taxes paid       150  
Non-cash investing and financing activities:          
Net unrealized (gain) loss on investments     418 11  
Exercise of private placement warrants       149,904  
Common Stock issued for acquisitions       208,989  
Common Stock issued for acquisition of in-process research and development       4,300  
Common Stock issued for settlement of contingent consideration     500    
Cash held back in acquisitions       50  
Additions to right of use assets and lease liabilities     10,742 891  
Purchase of property and equipment included in accounts payable     1,507 77  
Purchase of property and equipment included in accrued expense       33  
Contingent consideration in connection with acquisitions       $ 6,083  
Transfers from property and equipment to inventory     2,470    
Transfers from inventory to property and equipment     3,475    
Deferred contract costs     $ 1,341